The Multifaceted Role of MiR-21 in Pancreatic Cancers

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Jun 19

PMID 38891080

Authors

Clare Chen

Lusine Demirkhanyan

Christopher S Gondi

Affiliations

Soon will be listed here.

Abstract

With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among various biomarkers, microRNA-21 (miR-21), a small non-coding RNA, is highly expressed in PDAC. By inhibiting regulatory proteins at the 3' untranslated regions (UTR), miR-21 holds significant roles in PDAC cell proliferation, epithelial-mesenchymal transition, angiogenesis, as well as cancer invasion, metastasis, and resistance therapy. We conducted a systematic search across major databases for articles on miR-21 and pancreatic cancer mainly published within the last decade, focusing on their diagnostic, prognostic, therapeutic, and biological roles. This rigorous approach ensured a comprehensive review of miR-21's multifaceted role in pancreatic cancers. In this review, we explore the current understandings and future directions regarding the regulation, diagnostic, prognostic, and therapeutic potential of targeting miR-21 in PDAC. This exhaustive review discusses the involvement of miR-21 in proliferation, epithelial-mesenchymal transition (EMT), apoptosis modulation, angiogenesis, and its role in therapy resistance. Also discussed in the review is the interplay between various molecular pathways that contribute to tumor progression, with specific reference to pancreatic ductal adenocarcinoma.

Citing Articles

Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.

Hara T, Meng S, Alshammari A, Hatakeyama H, Arao Y, Saito Y Diagnostics (Basel). 2025; 15(5).

PMID: 40075875 PMC: 11899240. DOI: 10.3390/diagnostics15050628.

miR-29a-3p orchestrates key signaling pathways for enhanced migration of human mesenchymal stem cells.

Kang D, Kim T, Choi G, Park A, Yoon J, Yu J Cell Commun Signal. 2024; 22(1):365.

PMID: 39020373 PMC: 11256664. DOI: 10.1186/s12964-024-01737-0.

References

Timar J, Kashofer K . Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020; 39(4):1029-1038. PMC: 7680318. DOI: 10.1007/s10555-020-09915-5. View

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Won E, Park H, Yoon T, Cho Y . Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics. Pharmaceutics. 2022; 14(1). PMC: 8780888. DOI: 10.3390/pharmaceutics14010137. View

Debnath J, Gammoh N, Ryan K . Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023; 24(8):560-575. PMC: 9980873. DOI: 10.1038/s41580-023-00585-z. View

Enzler T, Shi J, McGue J, Griffith B, Sun L, Sahai V . A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions. Int J Mol Sci. 2024; 25(5). PMC: 10932200. DOI: 10.3390/ijms25052953. View

Gao L, Ren W, Zhang L, Li S, Kong X, Zhang H . PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma. Mol Carcinog. 2016; 56(4):1322-1334. DOI: 10.1002/mc.22594. View

Saiki Y, Jiang C, Ohmuraya M, Furukawa T . Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Cancers (Basel). 2022; 14(1). PMC: 8750056. DOI: 10.3390/cancers14010071. View

Bilimoria K, Bentrem D, Ko C, Stewart A, Winchester D, Talamonti M . National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173-80. PMC: 1933550. DOI: 10.1097/SLA.0b013e3180691579. View

10.

Wong M, Xue A, Julovi S, Pavlakis N, Samra J, Hugh T . Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2014; 20(15):4047-58. DOI: 10.1158/1078-0432.CCR-13-3377. View

11.

Shi G, Ye D, Yao X, Zhang S, Dai B, Zhang H . Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010; 31(7):867-73. PMC: 4007720. DOI: 10.1038/aps.2010.48. View

12.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

13.

Zhang H, Yang L, Zhu Y, Yao X, Zhang S, Dai B . Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2010; 71(3):326-31. DOI: 10.1002/pros.21246. View

14.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

15.

Chalhoub N, Baker S . PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2008; 4:127-50. PMC: 2710138. DOI: 10.1146/annurev.pathol.4.110807.092311. View

16.

Wang Y, Lee C . MicroRNA and cancer--focus on apoptosis. J Cell Mol Med. 2009; 13(1):12-23. PMC: 3823033. DOI: 10.1111/j.1582-4934.2008.00510.x. View

17.

Bishnoi S, Tiwari R, Gupta S, Byrareddy S, Nayak D . Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Viruses. 2018; 10(2). PMC: 5850397. DOI: 10.3390/v10020090. View

18.

Krantic S, Mechawar N, Reix S, Quirion R . Apoptosis-inducing factor: a matter of neuron life and death. Prog Neurobiol. 2007; 81(3):179-96. DOI: 10.1016/j.pneurobio.2006.12.002. View

19.

Ying H, Elpek K, Vinjamoori A, Zimmerman S, Chu G, Yan H . PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011; 1(2):158-69. PMC: 3186945. DOI: 10.1158/2159-8290.CD-11-0031. View

20.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View